Lung Cancer

"He strengthens you with the scientific knowledge he provides, with his courage as a role model and with his fighting spirit.”

A patient writes about the impact Dr. Aaron Mansfield had on her during treatment.

From a 6-year-old cancer survivor visiting all 50 states to give wagons to pediatric patients to Kathy Griffin taking an honest look at cancer and opioid addiction, here’s what’s happening in the cancer space this week.

Patients who quit smoking after receiving a diagnosis of non-small cell lung cancer may have an almost two-year survival benefit than those who continued to smoke.

The 60-year-old comedian is optimistic about her prognosis.

"Although there is no shortage of problems to be solved across the health landscape, Marty made his bio debut by tackling one of the biggest addressable markets in oncology: lung cancer."

Articles containing misinformation on social media sites like Facebook and Twitter were more likely to be shared and liked than those with accurate information.

An oncologist writes about a local cancer care leader who developed an impressive multidisciplinary cancer team.

Join CURE® for the Educated Patient® Webinar: Individualized Treatment for Small Cell Lung Cancer on Thursday, August 26.

Online resources available to patients with lung or thyroid cancer who are considering participation in a clinical trial after undergoing comprehensive genomic profiling.

The pros and cons of conducting pathology assessments for comprehensive biomarker tests in central laboratories versus local laboratories.

"Hildy’s creative energy in founding and nurturing Upstage Lung Cancer has made many more people aware of the disease," one man writes.

A patient with small cell lung cancer nominates writes about the woman who connected her to others with the same diagnosis.

Patients with heart failure may have an increased incidence of cancer, which may be a result of similar risk factors including obesity and diabetes.

A cancer survivor writes about the oncologist who helped him conquer the fears and anxieties of cancer treatments.

The FDA’s recent approval of Rybrevant marks the first targeted therapy for a certain group of patients with non-small cell lung cancer, according to an expert at NYU Langone Health’s Perlmutter Cancer Center.

Katie Brown, senior vice president of survivorship and support for LUNGevity Foundation, wrote about a program for patients to gain knowledge from survivors.

"Jutta Becker does not wear a cape and she cannot fly, but she does soar," writes a colleague nominating Becker for the Lung Cancer Heroes® award.

Deborah Pickworth, who is living with stage 4 lung cancer, was nominated for the Lung Cancer Heroes® award for her impact in supporting and advocating for others with the disease.

A survivor with a nearly 10-year journey with lung cancer and ongoing treatment writes a poem about the emotional ups and downs of living with cancer.

"Whereas scientific and organizational developments have been landmarks for Dr. Hirsch, his care for patients has always been in the center and, as a cancer survivor himself, he will always have patient care at the forefront."

"Although Carolyn loved her role as a navigator, she realized she could help patients with lung cancer with a screening program to help with earlier detection."

In this episode of the “CURE® Talks Cancer” podcast, Dr. Thomas Marron of the Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai in New York discusses the exciting future of cancer vaccines.

Lori J. Wirth, MD, describes what information she looks for from results of molecular testing that help inform treatment for her patients with thyroid cancer.

Andrea Ferris, of the LUNGevity Foundation, explains why shared decision-making is important when recommending molecular testing to patients with lung or thyroid cancer and highlights resources provided through her organization that support patients and health care professionals.

Patients with metastatic KRAS G12C mutated non-small cell lung cancer now have another treatment option if they previously failed at least one line of therapy.

Novel combo regimen reduces number of toxic treatments in patients with NSCLC.

Common questions asked by patients with lung or thyroid cancer who have been referred for biomarker testing and advice for setting expectations from test results.

Drs Benjamin Levy and Lori J. Wirth comment on the current role of liquid biopsies in lung and thyroid cancer.

Recommendations for selecting appropriate patients for comprehensive genomic profiling and navigating through the testing process.